Full Text
PHP240 - HEALTH TECHNOLOGY ASSESSMENTS OF BEVACIZUMAB BIOSIMILARS- COULD A DEMONSTRATION OF COST-EFFECTIVENESS CHANGE THE RECOMMENDATION FOR REIMBURSEMENT VERSUS THE ORIGINATOR?

Abstract

Authors

A. Hnoosh D.F. Courmier

Back to Volume 21, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×